Most Prostate Cancer Does Not Need Initial Treatment

Scherger, Joseph E.
December 2010
Internal Medicine Alert;12/15/2010, Vol. 32 Issue 23, p179
A decision analysis shows that active surveillance is a good option for men age 65 and older with low-risk prostate cancer (Gleason score of 6 or less). Active surveillance results in the highest quality- of-life scores compared with different treatment options, and 61% of these men will go on to treatment after a median of 8.5 years, with a slight increased mortality risk. Only 10% of men currently receive active surveillance for low-risk prostate cancer.


Related Articles

  • Enzalutamide improved outcomes in prostate cancer regardless of age.  // Hem/Onc Today;4/10/2014, Vol. 15 Issue 7, p26 

    The article reports on the results of a clinical trial which found that prostate cancer patients, irregardless of age, have improved outcomes when they undergo treatment with antagonist drug enzalutamide.

  • Early docetaxel with ADT extended OS in metastatic prostate cancer.  // Hem/Onc Today;7/10/2014, Vol. 15 Issue 13, p1 

    The article discusses a study by Christopher Sweeney and colleagues, presented at the American Society of Clinical Oncology's annual meeting, about the role of adding docetaxel to initial androgen deprivation therapy in extending the overall survival of patients with metastatic prostate cancer.

  • The Role of Radical Prostatectomy in the Treatment of Patients with High-Risk Prostate Cancer. Kuzgunbay, Barış; Yaycıoğlu, Özgür // Journal of Urological Surgery;Sep2015, Vol. 2 Issue 3, p120 

    High-risk prostate cancer (PCa), which is defined as PSA >20 ng/mL or Gleason Score (GS) >7 or ≥cT3a, accounts for up to 40% of newly diagnosed cases and carries a significant risk of progression and death. However, the best management approach for patients with high-risk PCa is still...

  • Predictability and Management of OARs Toxicity in Patients with Prostate Cancer Treated with High-Dose Radiotherapy. Ravo, Vincenzo; Borrelli, Domenico; Falivene, Sara; Di Franco, Rossella; Muto, Matteo; Argenone, Angela; Borzillo, Valentina; Cammarota, Fabrizio; Muto, Paolo // Journal of Cancer Therapy;Dec2013, Vol. 4 Issue 10, p1452 

    Aim: To evaluate the predictability of toxicity analyzing the dose-volume histograms (DVHs) and to verify the effectiveness of preventive measures limiting side toxicity considering the evolution of the radiation techniques for prostate cancer treatment. Materials and Methods: 208 patients with...

  • Drug Benefits Metastatic PCa Patients.  // Renal & Urology News;Apr2010, Vol. 9 Issue 4, p32 

    The article presents a study which shows that cabazitaxel extends survival better than mitoxantrone in patients having metastatic castration-resistant prostate cancer (mCRPC) who had failed previous docetaxel treatment.

  • Aggressive Treatment May Not Be Best For Older, Sicker Prostate Cancer Patients.  // Healthy Years;Jul2014, Vol. 11 Issue 7, p7 

    The article discusses a study that found the unsuitability of aggressive treatment for prostate cancer patients who are older and sicker which can also lead to debilitating side effects including urinary incontinence and impotence as published in the "Cancer" journal.

  • Lessons From the CaPSURE Database. Cooperberg, Matthew R. // AUANews;Oct2008, Vol. 13 Issue 10, p9 

    This article explores lessons learned from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry. CaPSURE is an observational database of patients with prostate cancer treated at a variety of clinical practice settings throughout the U.S. A study by CaPSURE in 2008...

  • Enzalutamide extended OS, PFS in chemotherapy-naive prostate cancer.  // Hem/Onc Today;3/10/2014, Vol. 15 Issue 5, p25 

    The article discusses research being done on the use of enzalutamide in patients with metastatic castration-resistance prostate cancer, which references a study by Tomasz M. Beer et al. presented at the 2014 Genitourinary Cancers Symposium in San Francisco, California.

  • High Risk Prostate Cancer: the Best Indication for Radical Prostatectomy. Van Poppel, Hendrik // AUANews;Apr2013, Vol. 18 Issue 4, p20 

    The article reports that as of 2013, the radical treatment options for high risk prostate cancer (Pca) are radiotherapy (RT) and radical prostatectomy (RP). Since 10-year cancer specific survival (CSS) rates of more than 90% have been described, surgery for high risk Pca is gaining popularity. A...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics